Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/30435
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tüzün, Türkan | - |
dc.contributor.author | Sayın Kutlu, Selda | - |
dc.contributor.author | Kutlu, Murat | - |
dc.contributor.author | Kaleli, İlknur | - |
dc.date.accessioned | 2020-06-08T12:13:17Z | |
dc.date.available | 2020-06-08T12:13:17Z | |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1300-0144 | - |
dc.identifier.uri | https://hdl.handle.net/11499/30435 | - |
dc.identifier.uri | https://doi.org/10.3906/sag-1902-24 | - |
dc.description.abstract | Background/aim: Community-onset urinary tract infections (UTIs) caused by extended-spectrum ß-lactamase (ESBL)-producing Escherichia coli have increased in many parts of the world. This study aimed to determine the prevalence and risk factors for community-onset UTI caused by ESBL-producing E. coli. Materials and methods: This prospective cohort study was conducted between January 2012 and March 2014 in cases of community-onset UTI caused by E. coli. Patients with UTI due to ESBL-producing E. coli and patients with UTI due to non-ESBL-producing E. coli were compared to identify risk factors for ESBL-producing E. coli in the community. Results: A total of 305 patients (116 males [46.4%]; mean age: 57.76 ± 18.06 years) were included in the study. Among these patients, 154 (50.5%) were infected with ESBL-producing E. coli. In multivariate analysis, the healthcare-associated UTI (odds ratio [OR]: 1.80; 95% confidence interval [CI]: 1.02–3.18; P = 0.041), upper urinary tract infection (OR: 3.05; 95% CI: 1.76–5.29; P < 0.0001), use of antibiotics in the preceding 6 months (OR: 2.28; 95% CI: 1.21–4.30; P = 0.011), and having two or more risk factors (OR: 4.03; 95% CI: 1.73–9.35; P = 0.001) were the significant factors associated with increased risk of community-onset UTIs due to ESBL-producing E. coli. Conclusion: The increasing prevalence of ESBL-producing E. coli makes it difficult to decide the empirical therapy in UTIs, especially in patients with two or more of the risk factors. A better understanding of the epidemiology and risk factors associated with community-onset UTIs due to ESBL-producing E. coli may have significant implications in decision-making for empirical antimicrobial treatment. © TÜBİTAK. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Turkiye Klinikleri | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Community-onset | en_US |
dc.subject | Epidemiology | en_US |
dc.subject | Extended-spectrum ß-lactamase | en_US |
dc.subject | Risk factors | en_US |
dc.subject | Urinary tract infections | en_US |
dc.subject | amoxicillin plus clavulanic acid | en_US |
dc.subject | antibiotic agent | en_US |
dc.subject | beta lactamase inhibitor | en_US |
dc.subject | cefotaxime | en_US |
dc.subject | ceftazidime | en_US |
dc.subject | cephalosporin | en_US |
dc.subject | ciprofloxacin | en_US |
dc.subject | clavulanic acid | en_US |
dc.subject | extended spectrum beta lactamase | en_US |
dc.subject | fluoroquinolone | en_US |
dc.subject | gentamicin | en_US |
dc.subject | nitrofurantoin | en_US |
dc.subject | piperacillin plus tazobactam | en_US |
dc.subject | quinolone derivative | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | antiinfective agent | en_US |
dc.subject | bacterial protein | en_US |
dc.subject | beta lactamase | en_US |
dc.subject | adolescent | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | antibiotic sensitivity | en_US |
dc.subject | antimicrobial therapy | en_US |
dc.subject | Article | en_US |
dc.subject | bacterial growth | en_US |
dc.subject | bacterium isolate | en_US |
dc.subject | cohort analysis | en_US |
dc.subject | colony forming unit | en_US |
dc.subject | community | en_US |
dc.subject | community onset urinary tract infection | en_US |
dc.subject | controlled study | en_US |
dc.subject | decision making | en_US |
dc.subject | disk diffusion | en_US |
dc.subject | extended spectrum beta lactamase producing Escherichia coli | en_US |
dc.subject | female | en_US |
dc.subject | healthcare associated infection | en_US |
dc.subject | hospitalization | en_US |
dc.subject | human | en_US |
dc.subject | human versus nonhuman data | en_US |
dc.subject | kidney failure | en_US |
dc.subject | length of stay | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | neoplasm | en_US |
dc.subject | prevalence | en_US |
dc.subject | prospective study | en_US |
dc.subject | risk factor | en_US |
dc.subject | urinalysis | en_US |
dc.subject | urinary tract infection | en_US |
dc.subject | urine culture | en_US |
dc.subject | very elderly | en_US |
dc.subject | community acquired infection | en_US |
dc.subject | drug effect | en_US |
dc.subject | enzymology | en_US |
dc.subject | Escherichia coli | en_US |
dc.subject | Escherichia coli infection | en_US |
dc.subject | microbial sensitivity test | en_US |
dc.subject | microbiology | en_US |
dc.subject | middle aged | en_US |
dc.subject | multidrug resistance | en_US |
dc.subject | pathogenicity | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Anti-Bacterial Agents | en_US |
dc.subject | Bacterial Proteins | en_US |
dc.subject | beta-Lactamases | en_US |
dc.subject | Community-Acquired Infections | en_US |
dc.subject | Drug Resistance, Multiple, Bacterial | en_US |
dc.subject | Escherichia coli Infections | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Microbial Sensitivity Tests | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Prospective Studies | en_US |
dc.subject | Risk Factors | en_US |
dc.subject | Urinary Tract Infections | en_US |
dc.title | Risk factors for community-onset urinary tract infections caused by extended-spectrum ß-lactamase-producing escherichia coli | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 49 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 1206 | |
dc.identifier.startpage | 1206 | en_US |
dc.identifier.endpage | 1211 | en_US |
dc.authorid | 0000-0002-6443-3628 | - |
dc.authorid | 0000-0003-0640-1019 | - |
dc.identifier.doi | 10.3906/sag-1902-24 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 31385490 | en_US |
dc.identifier.scopus | 2-s2.0-85071354472 | en_US |
dc.identifier.trdizinid | 336589 | en_US |
dc.identifier.wos | WOS:000480360000035 | en_US |
dc.identifier.scopusquality | Q3 | - |
dc.owner | Pamukkale University | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Murat Kutlu.pdf | 226.49 kB | Adobe PDF | View/Open |
CORE Recommender
Sorry the service is unavailable at the moment. Please try again later.
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.